Beyond type 2 diabetes and weight loss, GLP-1 agonists can also help lower blood pressure, improve lipid disorders, reduce ...

Health-care professionals, eager to support their patients diagnosed with diabetes or obesity, are writing more prescriptions ...

While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that ...

The deal gives the Swiss pharma access to an experimental amylin-targeting treatment it will test in combination with drugs ...

PatchMD, a leading innovator in transdermal nutrient delivery, is excited to announce the launch of its new GLP-1 Support ...

Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this ...

In a world inundated with weight loss products and miracle supplements, it can be overwhelming to determine what truly works. Enter LipoVive, a groundbreaking supplement that has captured the ...

Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to ...

Roche partners with Zealand Pharma on obesity drug petrelintide, with a $5.3B deal including milestone payments and global ...